Our gene therapies are designed to halt or reverse progression of lysosomal disorders with a single infusion. Learn about us, our focus and technology, sign up for updates, and read articles to expand your gene therapy knowledge.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $85M
Founded date: 2015
Founders name: Chris Mason
Founders Related Locations: United Kingdom, England, London; United States, District of Columbia, Washington; United States, Massachusetts, Cambridge; United States, Pennsylvania, Pittsburgh
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.02.2018 | Series B | $60M | - |
| 02.08.2016 | Series A | $25M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Chris | Mason | Founder &a... | linkedin.c... | - | - |
Mentions in press and media 17
| Date | Title | Description |
| 14.08.2025 | The Power of Global Partnerships in Gene Therapy | Share Share Share Share Email Gene therapy, once an ambitious vision of modern medicine, is rapidly becoming a transformative reality for patients worldwide. As technologies mature and the industry faces both headwinds and promise, it’s not... |
| 29.05.2018 | Top tech startup news stories you need to know this Tuesday, May 29 | Good morning! Here are some of the top tech startup news stories for today, Tuesday, May 29. Investors are betting $4 billion on a cryptocurrency startup, Block.One. Back in January of this year, we covered the hottest blockchain startups ... |
| 05.02.2018 | Capitalizing on a gene therapy boom, Avrobio locks in $60M | Announced Thursday, the raise was co-led by Cormorant Asset Management and Surveyor Capital, with support from Aisling, Brace Pharma Capital, Eventide, Morningside and Leerink Partners. Early backers Atlas Venture, SV Health Investors, and ... |
| 02.02.2018 | Term Sheet — Friday, February 2 | IPO DELAYS Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop In an executive shakeup, Airbnb said its CFO, Laurence “L.T.” Tosi will be leaving the company and CEO Brian Chesky’s longtime deput... |
| 01.02.2018 | AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | Company to initiate Phase 2 trial with lead gene therapy, AVR RD 01, based on promising initial clinical data in Fabry disease |
| 01.02.2018 | AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announced today that it has completed a $60 million Series B financing. Procee... |
| 01.02.2018 | AVROBIO Receives $60M Series B Funding | CAMBRIDGE, MA, AVROBIO announced today that it has completed a $60 million Series B financing. >> Click here for more funding data on AVROBIO >> To export AVROBIO funding data to PDF and Excel, click here AVROBIO, a clini... |
| 01.02.2018 | Avrobio Raises $60M in Series B Financing | Avrobio, a Cambridge, Mass.-based clinical-stage biotechnology company developing gene therapies for rare diseases, completed a $60m Series B financing. The round was co-led by Cormorant Asset Management and Surveyor Capital (a Citadel comp... |
| 01.02.2018 | AVROBIO Raises $60M In Series B | AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, announced today that it has completed a $60 million Series B financing. Proceeds from the financing will be use... |
| 01.02.2018 | Avrobio pulls in $60M to push Fabry, Gaucher candidates through the clinic | Avrobio has raised $60 million in series B financing to “aggressively” advance its gene therapy pipeline for lysosomal storage disorders, including moving its lead asset, a treatment for Fabry disease, into phase 2. Based on its lentiviral ... |
Show more